Novel euglycemic and hypolipidemic agents. 1

被引：81

作者：

Lohray, BB ^{[1
]}

Bhusan, V ^{[1
]}

Rao, BP ^{[1
]}

Medhavan, GR ^{[1
]}

Murali, N ^{[1
]}

Rao, KN ^{[1
]}

Reddy, AK ^{[1
]}

Rajesh, BM ^{[1
]}

Reddy, PG ^{[1
]}

Chakrabarti, R ^{[1
]}

Vikramadithyan, RK ^{[1
]}

Rajagopalan, R ^{[1
]}

Mamidi, RNVS ^{[1
]}

Jajoo, HK ^{[1
]}

Subramanian, S ^{[1
]}

机构：

[1] Dr Reddys Res Fdn, Hyderabad 500050, Andhra Pradesh, India

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 1998年 / 41卷 / 10期

关键词：

D O I：

10.1021/jm970444e

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of [[(heterocyclyl)ethoxy]benzyl]-2,4-thiazolidinediones have been synthesized by the condensation of corresponding aldehyde 1 and 2,4-thiazolidinedione followed by hydrogenation. Both unsaturated thiazolidinedione 2 and its saturated counterpart 3 have shown antihyperglycemic activity. Many of these compounds have shown superior euglycemic and hypolipidemic activity compared to troglitazone (CS 045). The indole analogue DRF-2189 (3g) was found to be a very potent insulin sensitizer, comparable to BRL-49653 in genetically obese C57BL/6J-ob/ob and 57BL/KsJ-db/db mice. Pharmacokinetic and tissue distribution studies conducted on BRL-49653 and DRF-2189 (3g) indicate that these drugs are well-distributed in target tissues. On the basis of euglycemic activity as well as enhanced selectivity against reduction of triglycerides in plasma, DRF-2189 (3g) has been selected for further evaluation.

引用

页码：1619 / 1630

页数：12

共 50 条

[21] Liposomes: Delivery systems for novel therapeutic agents.
Taylor, PW
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 299 - PMSE
[22] Novel sulfonate derivatives: Potent antimitotic agents.
Gwaltney, SL
Imade, HM
Barr, KJ
Li, Q
Gehrke, L
Credo, RB
Warner, RB
Lee, JY
Nukkala, MA
Zielinski, NA
Frost, D
Sham, HL
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U24 - U24
[23] Novel fluorinated serotonin transporter imaging agents.
Oya, SI
Choi, SR
Hou, C
Kung, MP
Shiue, CY
Kung, HF
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 220 : U556 - U556
[24] Phenolic oxidation products as novel antitumour agents.
Westwell, AD
Berry, JM
Bradshaw, TD
Chew, EH
Matthews, CS
Monks, A
Schwalbe, CH
Stevens, MF
CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6205S - 6205S
[25] Bacteria as Novel Anti-Mesothelioma Agents.
Lansley, S.
Della Vergiliana, J. Varano
Creaney, J.
Lee, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S750 - S750
[26] Novel analogues of fumagillin as potential antiangiogenic agents.
Lamothe, S
Courchesne, M
Labrecque, D
Desfosses, H
Attardo, G
Angers, E
Jutras, D
Kadhim, S
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 145 - MEDI
[27] The development and study of novel thiazolidines as radioprotective agents.
Wilmore, BH
Roberts, JC
Cassidy, P
Dominick, P
Warters, RL
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U261 - U261
[28] Chemistry and biology of novel isoxazolinone antibacterial agents.
Snyder, LB
Barrett, JF
Beaulieu, D
Bronson, JJ
Clark, JM
D'Andrea, SV
DenBleyker, KL
Drain, RL
Frosco, M
Fung-Tomc, JC
Knipe, JO
Lawrence, LE
Mate, RA
Meng, ZX
Mosure, K
Russell, JW
Santone, KS
Stickle, TM
Taylor, D
Warr, GA
Yang, HY
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U181 - U181
[29] Novel channel blockers as cytostatic cancer agents.
Heady, TN
Haverstick, DM
Gray, LS
Macdonald, TL
CLINICAL CANCER RESEARCH, 1999, 5 : 3782S - 3782S
[30] Synthesis of novel fumagillin analogs as antiangiogenic agents.
Dai, XDB
Griffith, EC
Liu, JO
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U13 - U13

← 1 2 3 4 5 →